SCHEMBL7219677

SCHEMBL7219677

NOC(=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.60
TP53 P04637 1/20 0.60
SRD5A2 P31213 3/20 0.52
CA1 P00915 5/20 0.50
CA2 P00918 5/20 0.50
CA12 O43570 3/20 0.50
CA9 Q16790 3/20 0.50
CA3 P07451 2/20 0.50
CA6 P23280 2/20 0.50
CA5A P35218 2/20 0.50
CA7 P43166 2/20 0.50
CA14 Q9ULX7 2/20 0.50
CA5B Q9Y2D0 2/20 0.50
TYR P14679 1/20 0.50
DRD1 P21728 1/20 0.50
CA4 P22748 1/20 0.50
PARP15 Q460N3 1/20 0.48
PARP10 Q53GL7 1/20 0.48
ALDH1A1 P00352 2/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29067065 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
Methane SCHEMBL28783787 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL29067048 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL29067047 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL29067053 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL29067061 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL3893739 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL17262710 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL29067072 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2
SCHEMBL27790739 0.98 TSHR (0.57) TSHRTP53SRD5A2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115591583-B Preparation method and application of cellulose-MOF core-shell structure 北京理工大学 2024-07-30 CN claimed
CN-114039089-B Preparation method and application of amorphous MOF-based lithium-sulfur battery material 河北工业大学 2024-02-02 CN claimed
CN-116903869-A Zr-UiO-66-BA material, preparation method, application and saccharomyces cerevisiae concentration detection method 贵州茅台酒股份有限公司 2023-10-20 CN claimed
CN-114039089-A Preparation method and application of lithium-sulfur battery material based on amorphous MOF 河北工业大学 2022-02-11 CN claimed
EP-3595808-B1 ORGANIC - INORGANIC POROUS HYBRID MATERIAL, METHOD FOR OBTAINING IT AND USE THEREOF INDUSTRIAS QUIM DEL EBRO S A (ES) 2020-08-05 EP claimed
CN-106215964-B A kind of liberation of hydrogen catalyst and preparation method thereof 北京化工大学 2019-01-18 CN claimed
CN-101637465-A Medical application of 1-methyl-2-amino terephthalate TIANJIN MEDICAL UNEVERSITY CAN 2010-02-03 CN claimed
CN-1090374-C Circuit protective device comprising PTC condcutive liquid crystal polymer composition EATON CORP (US) 2002-09-04 CN claimed
CN-1149746-A Circuit protective device comprising PTC condcutive liquid crystal polymer composition EATON CORP (US) 1997-05-14 CN claimed
CN-122006499-A Composite nanofiber filter material for cooperatively removing particulate matters and sulfur dioxide and preparation method thereof 中国科学院城市环境研究所 2026-05-12 CN disclosed
CN-120129537-A Radiopharmaceutical MOF for medical imaging 诺德制药股份有限公司 2025-06-10 CN disclosed
US-20250144595-A1 METAL ORGANIC RESINS WITH PROTONATED AND AMINE-FUNCTIONALIZED ORGANIC MOLECULAR LINKERS NORTHWESTERN UNIVERSITY 2025-05-08 US disclosed
US-12233398-B2 Metal organic resins with zirconium nodes NORTHWESTERN UNIVERSITY (US) 2025-02-25 US disclosed
CN-115591583-B Preparation method and application of cellulose-MOF core-shell structure 北京理工大学 2024-07-30 CN disclosed
US-6602871-B2 Anticoagulants; compounds of given formula: several types of nitrogen containing heterocycles such as perhydroindolizine, piperazine, pyrimidine BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-08-05 US disclosed
CN-1090374-C Circuit protective device comprising PTC condcutive liquid crystal polymer composition EATON CORP (US) 2002-09-04 CN disclosed
US-20020115854-A1 Thrombin or factor Xa inhibitors LAM PATRICK Y S (US) 2002-08-22 US disclosed
CN-1149746-A Circuit protective device comprising PTC condcutive liquid crystal polymer composition EATON CORP (US) 1997-05-14 CN disclosed
US-5324832-A Muscarinic antagonists THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1994-06-28 US disclosed
WO-1993000906-A1 MUSCARINIC ANTAGONISTS THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 1993-01-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115854-A1 Thrombin or factor Xa inhibitors SERPINC1, TFPI, SPINT2 TSHR 1175/4885TP53 3061/4885SRD5A2 1452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.